Welcome to our dedicated page for Novocure SEC filings (Ticker: NVCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovoCure Limited filings document the oncology device company's operating results, product and regulatory updates, and governance for its Tumor Treating Fields business. Recent Form 8-K reports include quarterly and annual financial results, FDA approval disclosure for Optune Pax, clinical-trial updates for pancreatic cancer, Medicare billing-status disclosure and executive compensatory arrangements.
Proxy materials describe board matters, executive compensation, equity awards and shareholder voting items. The filing record also identifies NovoCure as a Jersey-incorporated registrant under the Nasdaq ticker NVCR and records formal disclosures tied to its commercial products, clinical programs and reimbursement matters.
NovoCure Ltd reported an insider equity award for its General Counsel, Ben Arye Barak. He acquired 17,755 ordinary shares on February 28, 2026 at a stated price of $0.00 per share, described as the vesting of performance-based restricted stock units.
Following this grant/vesting, Barak’s direct holdings increased to 192,328 ordinary shares. This transaction reflects stock-based compensation rather than an open-market purchase or sale.
Morgan Stanley Smith Barney LLC reported a Form 144 disclosing an insider sale: Francis Leonard sold 9,734 common shares of NVCR on 02/27/2026 for $133,003.43. The filing also lists 5,507 performance shares and 1,725 restricted stock with trade dates 02/28/2026.
Morgan Stanley Smith Barney LLC Executive Financial Services submitted a Form 144 notice reporting proposed sales of company equity. The filing lists 818 Restricted Stock and 2,454 Performance Shares dated 02/28/2026. It also reports sales of 7,461 common shares on 02/27/2026 for $103,256.51.
NovoCure Limited is a global oncology company focused on Tumor Treating Fields (TTFields), a medical device–delivered electric field therapy designed to disrupt cancer cell division. Its main commercial products are Optune Gio for glioblastoma, Optune Lua for metastatic non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer.
The company generates most revenue from Optune Gio use in the U.S., Germany, France and Japan, and is pursuing broader reimbursement and geographic expansion. NovoCure highlights positive late‑stage data, including the METIS brain metastases trial, and is advancing multiple Phase 2 and 3 studies in GBM, NSCLC and pancreatic cancer while emphasizing extensive regulatory, manufacturing, reimbursement and competition risks.
Novocure Limited reported modest growth in 2025 while advancing its cancer therapy portfolio. Full year net revenues reached $655.4 million, up 8%, with fourth quarter net revenues of $174.4 million, also up 8%, driven by more active patients on Tumor Treating Fields therapy.
Net loss improved to $136.2 million for 2025 and $24.5 million in the fourth quarter, with quarterly loss per share of $0.22. Adjusted EBITDA was $(16.4) million for the quarter and $(34.3) million for the year, reflecting high R&D and commercialization spending.
Novocure ended 2025 with $447.7 million in cash, cash equivalents and short-term investments and 4,620 active patients on therapy. In early 2026, the FDA approved Optune Pax for locally advanced pancreatic cancer, public payers in Czechia and British Columbia expanded Optune Gio coverage, and CMS reversed a temporary revocation of U.S. billing privileges. The company guided 2026 net revenues to $675–$705 million and Adjusted EBITDA between $(20) million and $0.
Novocure Limited reported that Medicare billing privileges for its U.S. subsidiary were temporarily revoked and then fully restored. CMS had revoked billing for the company’s products retroactive to December 17, 2025 due to an administrative issue with a triannual re-validation process, not a substantive qualification failure.
On February 24, 2026, CMS rescinded the revocation and reinstated Medicare billing privileges retroactive to December 17, 2025. Novocure states it continued serving existing and new patients throughout this period and believes there will ultimately be no impact on its ability to recognize revenue for those services.
Soleus Capital Master Fund, L.P. and affiliated entities filed an amended ownership report on NovoCure Limited. They report beneficial ownership of 8,530,665 ordinary shares, representing 7.6% of NovoCure’s ordinary shares, based on 111,981,981 shares outstanding as of October 24, 2025.
The group has shared voting and dispositive power over all reported shares and no sole voting or dispositive power. The filing is made on a passive basis, certifying that the securities were not acquired to change or influence control of NovoCure.
Novocure Limited announced that the U.S. FDA approved Optune Pax, a wearable Tumor Treating Fields device, for adult patients with locally advanced pancreatic cancer when used with gemcitabine and nab-paclitaxel. This is described as the first FDA‑approved treatment in nearly 30 years for this disease stage.
In the Phase 3 PANOVA‑3 trial (571 patients), Optune Pax plus chemotherapy improved median overall survival to 16.2 months versus 14.2 months in the intent‑to‑treat group and to 18.3 months versus 15.1 months in the modified per protocol group, with statistically significant hazard ratios. One‑year survival rates and time to pain progression also improved, while safety was mainly limited to expected skin reactions under the arrays and fatigue, with no device‑related deaths or unanticipated safety issues.